These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31826177)

  • 41. Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer.
    Segalés L; Juanpere N; Gallarín N; Lorenzo M; López D; Perera-Bel J; Rodriguez-Vida A; Fumadó L; Cecchini L; Bellmunt J; Lloreta-Trull J; Hernández-Llodrà S
    Virchows Arch; 2024 Aug; 485(2):281-290. PubMed ID: 38017230
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma.
    Nagle RB; Algotar AM; Cortez CC; Smith K; Jones C; Sathyanarayana UG; Yun S; Riley J; Nagy D; Dittamore R; Dalkin B; Brosh L; Pestano G
    Prostate; 2013 Aug; 73(11):1233-40. PubMed ID: 23653096
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer.
    Abou-Ouf H; Ghosh S; Box A; Palanisamy N; Bismar TA
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1751-1759. PubMed ID: 31129769
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
    Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
    Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer.
    Jacobsen F; Kraft J; Schroeder C; Hube-Magg C; Kluth M; Lang DS; Simon R; Sauter G; Izbicki JR; Clauditz TS; Luebke AM; Hinsch A; Wilczak W; Wittmer C; Büscheck F; Höflmayer D; Minner S; Tsourlakis MC; Huland H; Graefen M; Budäus L; Thederan I; Salomon G; Schlomm T; Melling N
    Neoplasia; 2017 Sep; 19(9):707-715. PubMed ID: 28830008
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone.
    Liu S; Yoshimoto M; Trpkov K; Duan Q; Firszt M; Corcos J; Squire JA; Bismar TA
    Cancer Biol Ther; 2011 Mar; 11(6):562-6. PubMed ID: 21178509
    [TBL] [Abstract][Full Text] [Related]  

  • 47. TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer.
    Fisher KW; Zhang S; Wang M; Montironi R; Wang L; Baldrige LA; Wang JY; MacLennan GT; Williamson SR; Lopez-Beltran A; Cheng L
    Mol Carcinog; 2017 Mar; 56(3):814-820. PubMed ID: 27500376
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma.
    Morais CL; Guedes LB; Hicks J; Baras AS; De Marzo AM; Lotan TL
    Hum Pathol; 2016 Sep; 55():117-25. PubMed ID: 27189342
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2.
    Mao N; Gao D; Hu W; Gadal S; Hieronymus H; Wang S; Lee YS; Sullivan P; Zhang Z; Choi D; Rosen N; Sawyers CL; Gopalan A; Chen Y; Carver BS
    Cancer Res; 2020 Apr; 80(7):1428-1437. PubMed ID: 32015092
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of PTEN deletion and ERG rearrangement on recurrence after treatment for prostate cancer: a systematic review and meta-analysis.
    Liu R; Zhou J; Xia S; Li T
    Clin Transl Oncol; 2020 May; 22(5):694-702. PubMed ID: 31359337
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.
    Burdelski C; Kleinhans S; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wilczak W; Marx A; Sauter G; Wittmer C; Huland H; Simon R; Schlomm T; Steurer S
    Int J Cancer; 2016 Mar; 138(5):1199-206. PubMed ID: 26383228
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PTEN Loss in a Prostate Cancer Cohort From Jordan.
    Al Bashir S; Alzoubi A; Alfaqih MA; Kheirallah K; Smairat A; Haddad H; Al-Dwairy A; Fawwaz BAB; Alzoubi M; Trpkov K
    Appl Immunohistochem Mol Morphol; 2020; 28(5):389-394. PubMed ID: 30614821
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increased association of the ERG oncoprotein expression in advanced stages of prostate cancer in Filipinos.
    Raymundo EM; Diwa MH; Lapitan MC; Plaza AB; Sevilleja JE; Srivastava S; Sesterhenn IA
    Prostate; 2014 Aug; 74(11):1079-85. PubMed ID: 24909781
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
    Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
    Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers.
    Burdelski C; Bujupi E; Tsourlakis MC; Hube-Magg C; Kluth M; Melling N; Lebok P; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Simon R; Schlomm T; Steurer S; Krech T
    PLoS One; 2015; 10(6):e0128525. PubMed ID: 26030748
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR.
    Simper NB; Jones CL; MacLennan GT; Montironi R; Williamson SR; Osunkoya AO; Wang M; Zhang S; Grignon DJ; Eble JN; Tran T; Wang L; Baldrige LA; Cheng L
    Hum Pathol; 2015 Jun; 46(6):805-12. PubMed ID: 25870120
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients.
    Almami A; Hegazy SA; Nabbi A; Alshalalfa M; Salman A; Abou-Ouf H; Riabowol K; Bismar TA
    Tumour Biol; 2016 Jul; 37(7):9731-8. PubMed ID: 26803516
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
    Weidemann SA; Sauer C; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Fraune C; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Heumann A
    BMC Cancer; 2019 Oct; 19(1):944. PubMed ID: 31606028
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.
    Morais CL; Herawi M; Toubaji A; Albadine R; Hicks J; Netto GJ; De Marzo AM; Epstein JI; Lotan TL
    Prostate; 2015 Oct; 75(14):1610-9. PubMed ID: 26178158
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.
    Brooks JD; Wei W; Hawley S; Auman H; Newcomb L; Boyer H; Fazli L; Simko J; Hurtado-Coll A; Troyer DA; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Feng Z; McKenney JK
    PLoS One; 2015; 10(7):e0132343. PubMed ID: 26172920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.